1. Co-expression of RAGE and HMGB1 is associated with cancer progression and poor patient outcome of prostate cancer
- Author
-
Chu-Biao, Zhao, Ji-Ming, Bao, Yong-Jie, Lu, Tong, Zhao, Xin-Hua, Zhou, Da-Yong, Zheng, and Shan-Chao, Zhao
- Subjects
endocrine system diseases ,cardiovascular system ,nutritional and metabolic diseases ,chemical and pharmacologic phenomena ,Original Article ,human activities - Abstract
Receptor for advanced glycation end products (RAGE), along with its ligand high mobility group box 1 (HMGB1), is believed to play an important role in prostate cancer. The aim of this retrospective study was to investigate the expression of RAGE and HMGB1 and their clinical impact on prostate cancer progression and prognosis. The expression of RAGE and HMGB1 was assessed by immunohistochemistry in cancer lesions from 85 confirmed prostate cancer cases. We determined the potential association between the expression level of these two proteins and the clinicopathological features and overall patient survival. RAGE and HMGB1 were expressed in 78.8% (67/85) and 68.2% (58/85) cases of prostate cancer, respectively, and in the majority (54/85) of cases, these two proteins were co-expressed. There was a strong correlation between RAGE and HMGB1 expressions (P
- Published
- 2014